Kessler Topaz Meltzer & Check, LLP - INVESTOR DEADLINE ALERT: Capricor Therapeutics, Inc. (CAPR) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

A securities fraud class action lawsuit has been filed against Capricor Therapeutics (CAPR) for allegedly making material misstatements regarding its lead product Deramiocel's statistical analysis plan and FDA compliance. The FDA revealed that Capricor made undisclosed changes to the pre-specified statistical analysis plan without prior FDA agreement, leading to FDA disagreement with the methodology. Following the FDA's unfavorable briefing documents on July 27, 2026, Capricor's stock price fell 64%. Investors who purchased CAPR securities between December 17, 2025 and July 26, 2026 can seek lead plaintiff status by September 28, 2026.